OTCPK:TLPPF (Australia)
Â
Ordinary Shares
$
10
-0.040 (-0.4%)
10:08 PM EST
Business Description
Telix Pharmaceuticals Ltd
ISIN : AU000000TLX2
Share Class Description:
TLPPF: Ordinary SharesTotal Employee Number:
1,184Compare
Compare
Traded in other countries / regions
TLX.AustraliaTLX.USAT3X.GermanyTLX1 N.Mexico IPO Date
2018-07-23Description
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.3 | |||||
Equity-to-Asset | 0.36 | |||||
Debt-to-Equity | 1.13 | |||||
Debt-to-EBITDA | 13.19 | |||||
Interest Coverage | 0.45 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 3.47 | |||||
Beneish M-Score | -1.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 93 | |||||
3-Year EPS without NRI Growth Rate | 39.4 | |||||
3-Year FCF Growth Rate | -3.9 | |||||
3-Year Book Growth Rate | 93.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 17.15 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 67.16 | |||||
9-Day RSI | 61.75 | |||||
14-Day RSI | 56.61 | |||||
3-1 Month Momentum % | 11.84 | |||||
6-1 Month Momentum % | 20.97 | |||||
12-1 Month Momentum % | -39.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 0.61 | |||||
Days Inventory | 31.23 | |||||
Days Sales Outstanding | 51.94 | |||||
Days Payable | 61.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -7.31 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53.06 | |||||
Operating Margin % | 2.25 | |||||
Net Margin % | -0.88 | |||||
EBITDA Margin % | 4.36 | |||||
FCF Margin % | -7.6 | |||||
OCF Margin % | -2.15 | |||||
ROE % | -1.77 | |||||
ROA % | -0.64 | |||||
ROIC % | 2.38 | |||||
3-Year ROIIC % | 8.3 | |||||
ROC (Joel Greenblatt) % | 46.88 | |||||
ROCE % | 4.06 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 769.23 | |||||
PS Ratio | 4.05 | |||||
PB Ratio | 8.31 | |||||
EV-to-EBIT | 106.3 | |||||
EV-to-Forward-EBIT | 46.62 | |||||
EV-to-EBITDA | 106.3 | |||||
EV-to-Forward-EBITDA | 77.63 | |||||
EV-to-Revenue | 4.64 | |||||
EV-to-Forward-Revenue | 4.15 | |||||
EV-to-FCF | -61.51 | |||||
Price-to-GF-Value | 0.36 | |||||
Earnings Yield (Greenblatt) % | 0.94 | |||||
FCF Yield % | -1.77 |
Telix Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Telix Pharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-21 09:30 | In 56 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 55 days | ||
| Jefferies Global Healthcare Conference | 2026-06-03 11:40 | 9.00 (+0.00%) | ||
| William Blair 46th Annual Growth Stock Conference | 2026-06-02 09:00 | 9.20 (+3.02%) | ||
| General meeting for 2026 | 2026-05-21 10:00 | 9.75 (+0.00%) | ||
| Unlocking the Potential of PSMA Therapy: A Next-Generation Portfolio | 2026-04-29 19:30 | 10.25 (+0.00%) | ||
| Telix Pharmaceuticals Limited ProstACT Global Part 1 Readout Webcast | 2026-03-10 09:30 | 7.00 (+0.00%) | ||
| Investor Education Event The Future of Prostate Imaging: What do physicians want? | 2026-03-04 17:30 | 6.80 (+3.03%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-19 17:30 | 6.50 (+2.85%) | ||
| Annual report for 2025 | 2026-02-19 | 6.50 (+2.85%) |
Show
Entries
Guru Commentaries on OTCPK:TLPPF
No articles.
Press Release
Articles on Telix Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers